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Abstract 
BACKGROUND: Pregnancy-associated plasma protein A (PAPP-A), is a protease which releases Insulin-like 
growth factor. The role of this factor is stimulation of cell mitosis, differentiation and trophoblastic invasion of 
deciduas. Identification of patients with low PAPP-A (under 0.4 MoM in the first trimester has an influence on birth 
weight, attenuation of fetal growth, preeclampsia, birth and fetal demise. 
AIM: The main issue in the study is evaluating an influence of PAPP-A, calculated in the first trimester on the 
unfavourable outcome of pregnancy. 
MATERIAL AND METHODS: Seventy pregnant women with singleton pregnancy underwent first-trimester 
biochemical screening. The target group were women with PAPP-A below 0.4 MoM, and in control group, PAPP-
A were оver 0.4 MoM. There was an assessment of the influence on the mode of delivery, gestational week, the 
presence of intrauterine growth restriction, preeclampsia, temporary birth, intrauterine fetal demise and newborn 
condition. 
RESULTS: In target group, consisted of 35 patients, 16 were delivered at term. From 28 to 37 g.w.- were 7 
patient, 22-28 g.w.- 4 and 8 patients were under the 22 g.w (all with fetal demise) there were 19 pretemporary 
deliveries - 9 with Cesarean Section (SC). In the target group: 5 newborn wеre with IUGR, 6 women had 
preeclampsia, 1 had placental abruption. In control group were 35 patients: 28 delivered at term, 9 with SC, 26 
vaginal deliveries; with IUGR were 4 newborns. Two newborns were hypertrophic. 
CONCLUSION: There is a significant difference in unfavourable outcome in the cases with PAPP-A under 0.4 
Mom, particular in the group, with a PAPP-A value under 0.2 MoM. The patients delivered with SC with the main 
indications in utero hypoxia, growth restriction and elevated blood pressure had PAPP-A between 0.3-0.4 MoM. 
The patients with intrauterine fetal death and placental abruption in the most of the cases have PAPP-A value 
under 0.2 MoM. There is a need to be aware in these pregnancies to achieve the preventions of adverse 
outcome, to decrease perinatal morbidity and mortality. 
 
 
 
 
 
 
Introduction 
 
The concentration measurement of 
Pregnancy-associated plasma protein A in the first 
trimester of pregnancy (PAPP-A), is one of the 
combined biochemical screening methods for 
aneuploidies, according to the recommendations of 
the Fetal Medicine Foundation (FMF), the combined 
screening method in the first trimester of pregnancy 
[1]. 
PAPP-A is a protease for insulin-like growth 
factor binding protein 4 (IGFBP 4), which facilitate the 
degradation of this protein, resulting in the release of 
insulin growth factor (IGF). IGFBP has a great ability 
for modification of its structure and function, as a 
result of proteolytic degradation. The intact IGFBP 4 is 
a powerful inhibitor of IGF in vitro, suggesting that 
proteolysis acts as a positive regulator of the IGF- 
availability. PAPP-A isolated from the serum of the 
pregnant woman has an IGF-dependent protease 
activity of IGFBP-4. This protease has an important 
role in the local proliferative answer, acting by 
accelerating the cell division. It increases the 
bioavailability of IGF, which in return mediates the 
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trophoblast invasion of the decidua and modulates the 
transport of glucose and amino acids in the placenta 
[2]. A disorder in the release of IGF might be a cause 
for inappropriate placental perfusion, which would 
affect the fetal growth and other adverse conditions in 
pregnancy [3] [4].
 
PAPP-A is a placental secretory product, and 
its value is low in the first trimester. The 
syncytiotrophoblastic deficient forming can have a role 
in the abnormal placental secretion in affected 
pregnancies. Normally, the media for PAPP-A rises 
from 0.4 MoM in the 10
th
 gestational week to 
approximately 0.7 MoM in the 13
th
 gestational week, 
so the PAPP-A increases as the pregnancy progress. 
The low value of PAPP-A (< 0.4 MoM) could 
predict an adverse perinatal outcome that includes 
fetuses with intrauterine growth restriction (IUGR), 
preeclampsia, preterm birth, miscarriage and stillbirths 
[5] [6] [7]. 
 
 
Material and Methods 
 
This study was submitted and approved by 
the Ethical Review Committee of the Medical 
University in Skopje and is in adherence to the laws 
and regulations of the country in which the research 
was conducted. Written consent with patient 
permission was obtained from each patient. 
This prospective cohort study was conducted 
at the University Clinic for Obstetrics and Gynecology 
in Skopje included 75 successively admitted and 
delivered patients during the period of one year from 
January 2017 to December 2017. All delivered 
neonates were without a sign of congenital infection, 
malformation and chromosomopathies. 
The study was taken at the University Clinic of 
Gynecology and Obstetrics, Skopje. The analyses 
were performed at the Biochemical laboratory in the 
Clinic, till some patients (70 patients) was fulfilled. The 
selection of the patients was made consecutive from 
patients in whom a combined biochemical screening 
in the first trimester was performed. The patients were 
divided into two groups: the target group - 35 patients 
who delivered with values of PAPP-A below or equal 
to 0.4 MoM and a control group - 35 patients who 
delivered with values of PAPP-A over 0.4 MoM. All the 
patients had fetuses without chromosomal 
abnormalities. The data for the patients was collected 
by questionnaire that included anamnestic, 
demographic information, information about present 
pregnancy, personal, familial and obstetric history.  
Inclusion criteria for PE were the presence of 
proteinuria at least 0.5 g/L/24 hours, increase in 
systolic pressure for minimum 30 mmHg, and diastolic 
pressure 15mmHg, measured two times apart for six 
hours, compared with blood pressure before 
pregnancy.  
Exclusion criteria were underlying presidential 
morbidity: chronic hypertension, diabetes, renal 
disease, autoimmune and metabolic disease (NICE 
guidelines). Inclusion criteria for IUGR were 
birthweight less than 5
th
 percentile for gestational age 
and sex, and exclusion criteria were the presence of 
congenital infection, anomalies and 
chromosomopathies and mother who took medication, 
alcohol and with toxicomania. The placental abruption 
was clinically and histopathological proven, and 
exclusion criteria were rupture of membrane, uterine 
fibroid or other operation of the uterus. 
 
  Methods 
The concentrations of free β-HCG and PAPP-
A were measured from 5ml of the peripheral blood 
sample with vacutainer in a tube without 
anticoagulant. The samples were delivered to the 
laboratory at the Clinic. The present device-Siemens 
Healthier-Immulite 2000 XPi, with a method of 
chemiluminescence, and the risk was calculated by 
licensed software PRISCA version 5.2.1, which is 
integrated into the device and is used at the Clinic. 
The results are presented in absolute values 
and percentages. The target group is the one with 
PAPP-A below 0.4 MoM, and the control group is the 
one with values of PAPP-A over 0.4 MoM. The 
difference in the incidence of the qualitative 
parameters was analysed by Chi-squared test. The 
values of P < 0.05 were taken for statistical 
significance.  
SPSS V.20 was used for numeric and 
attributive parameters. Standard descriptive and 
analytical bivariant and multivariant methods were 
used. Statistical significance among attributive 
parameters was determined wit Chi-square test and 
numerical parameters with Student T-test. 
 
 
Results 
There is no significant difference in the 
prevalence of the patients in both groups, i.e. the age 
is not a risk factor that affects the value of PAPP-A in 
patients without chromosomopathies. 
The percentage of term deliveries in the target 
group was 47%, compared to the control group in 
which it was 80%. There was a significant percentage 
of deliveries before 22
nd
 gestational weeks in the 
target group - 22% compared to the same parameter 
in the control group - 0%. 
In the control group, the number of patients 
who delivered by Caesarean section was 9, and the 
number who delivered spontaneously was 26. 
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Table 1: Prevalence of complication in the patients 
PAPP-A value 
(МоМ) 
 
0.0 -0.10 0.11-0.20 0.21-0.30 0.31-0.40 Total > 0.4 
Control 
group 
Fetal loss 2 3 2 1 8 0 
Hypertension   1 5 6 2 
IUGR   3 2 5 4 
Placental abruption  1   1 0 
Preterm delivery 
(total= iatrogenic+ 
contractions) 
    11 7 
Fetal hypoxia   5 4 9 4 
 
In the target group, there were 8 pregnancies 
terminated with artificial abortion because of an 
intrauterine death of the fetus, 1 patient delivered a 
death fetus spontaneously, in the 31
st
 gestational 
week with preterm placental abruption. Although there 
is no significant difference in the delivery with 
Caesarean section, it should be noted that in the 
control group there were 7 preterm deliveries, 4 of 
them were delivered by Caesarean section, and 3 
were spontaneously delivered. 
Table 2: Complication and PAPP-A value 
Complica
tion 
number 
(%) 
Fetal 
loss 
Hypertensi
on with or 
without 
proteinuria 
IUGR Placental 
abruption 
Fetal hypoxia Without 
complication 
Total 
Target 
group 
8 
(22.8) 
6 (17.1) 5 (14.3) 1 (2.8) 9 (25.8) 6 (17.2) 35 (100) 
Control 
group 
0 (0) 2 (5.7) 4 (11.4) 0 (0) 4 (11.4) 25 (71.5) 35 (100) 
р value < 0.05 < 0.05 > 0.05 > 0.05 < 0.05 1.00  
 
 
 
Discussion 
 
The values of PAPP-A between 0.05 and 0.20 
MoM are associated with adverse outcomes, such as 
stillbirths and preterm placental abruption [8]. The 
received results correlate with the study from 2010 [9]. 
There is a significant difference in the adverse 
outcome of life born with PAPP-A values between 0.3 
and 0.4 MoM, compared to the control group. This 
group involves the patients who delivered a live-born 
infant by Caesarean section because of IUGR, fetal 
hypoxia and elevated blood pressure [10] [11]. There 
are many studies that prove the correlation between 
low values of PAPP-A below 0.4 MoM and the birth 
weight and fetal growth. In one retrospective cohort 
study, it is found positive predictive values for SGA of 
2.97 (95% CI from 1.1 to 6.4) [12].  
There is a significant difference in the adverse 
outcome in patients with values of PAPP-A below 0.4 
MoM, especially with values below 0.2 MoM. In the 
patients, who delivered by Caesarean section with a 
life born because of a fetal growth restriction, fetal 
hypoxia and elevated blood pressure in the 
pregnancy, the value of PAPP-A is 0.3 to 0.4 MoM. 
Patients with intrauterine fetal death and preterm 
placental abruption, have a value of PAPP-A below 
0.2 MoM, but having only 2 patients with this result, 
we can not interpret its statistical significance. The 
PAPP-A values interval between 0.3 and 0.4 MoM, 
showed more fetuses with growth restriction and 
preeclampsia, and iatrogenic preterm delivery 
because of the complications mentioned above. There 
is no significant difference in the number of 
spontaneous preterm delivery among the patients with 
a PAPP-A value below 0.4 MoM. The most of 
premature  deliveries in control group are due a 
premature rupture of membrane and premature 
contractions. 
To make an algorithm for following of these 
pregnancies, a huge series of a pregnant woman 
should be included, and more precise definition of the 
values of this protein should be done, that has a 
significant impact of the pregnancy outcome. In term 
of the fact that there is a national recommendation for 
follow up on patients with low values of PAPP-A in 
some countries, an attempt for its implementation in 
our country could be done [13]. The listed Australian 
recommendations for follow up of patients with low 
PAPP-A values (below 0.37 MoM - 5
th
 percentile), can 
be applied for the beginning as it is national approved 
and it covers a big group of patients. Caution should 
be taken about the obtained results, with a purpose of 
prevention of an adverse pregnancy outcome and 
decreasing the perinatal mortality and morbidity. It is 
necessary to assess the cost-benefit if these 
recommendations are going to be implemented in our 
circumstances. 
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